A Study of IDN-6556 in Subjects With Liver Cirrhosis

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Liver CirrhosisHepatic Cirrhosis
Interventions
DRUG

IDN-6556

25 mg BID

DRUG

Placebo

Trial Locations (28)

10016

NYU Medical Center, New York

10029

Mt. Sinai School of Medicine, New York

11030

North Shore University Hospital, Manhasset

19104

University of Pennsylvania, Philadelphia

19141

Einstein Healthcare Network, Philadelphia

23226

Bon Secours St. Mary's Hospital of Richmond, Inc., Richmond

23602

Bon Secours Mary Immaculate Hospital, Newport News

30309

Piedmont Atlanta Hospital, Atlanta

32610

University of Florida, Gainesville

33136

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

40202

University of Louisville, Louisville

45267

University of Cincinnati Physicians Company, LLC, Cincinnati

46202

Indiana University, Indianapolis

48202

Henry Ford Hospital, Detroit

60153

Loyola University Medical Cente, Maywood

60637

University of Chicago, Chicago

76104

Baylor All Saints Medical Center, Fort Worth

77030

Baylor College of Medicine, Houston

Baylor St. Luke's Medical Center, Houston

UT Health Science Center at Houston, Houston

84132

University of Utah Hospital, Salt Lake City

90048

Cedar-Sinai Medical Center, Los Angeles

92037

Scripps Clinic, La Jolla

92093

Univeristy of California, San Diego, San Diego

92354

Loma Linda University Medical Center, Loma Linda

94115

California Pacific Medical Center, San Francisco

07103

Rutgers New Jersey Medical School, Newark

Sponsors
All Listed Sponsors
lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT02230670 - A Study of IDN-6556 in Subjects With Liver Cirrhosis | Biotech Hunter | Biotech Hunter